News Wire

Looking for healthy folks? Take a trip to San Francisco or Seattle, WalletHub suggests. But if your journey takes you through Brownsville or Laredo, Texas, don’t bother stopping. With health care costs rising and U.S. life expectancy declining for the second year in a row, the personal-finance website…
The flu or pneumonia claimed the lives of one out of every 10 Americans who died during the week ending February 3, according to the Centers for Disease Control and Prevention (CDC). Throughout most of the nation, the flu appears to remain on the rise, Acting CDC Director Anne Schuchat, MD, said at…
The FDA has approved Biktarvy (Gilead Sciences, Inc.), a once-daily, single-tablet regimen for the treatment of HIV-1 infection that includes 50 mg of bictegravir, 200 mg of emtricitabine, and 25 mg of tenofovir alafenamide. Bictegravir is a novel, unboosted integrase strand transfer inhibitor (INSTI),…
Two federal agencies have acted to ensure a stable and secure supply of a critical radioactive imaging product used to detect potentially life-threatening diseases. The FDA has approved the RadioGenix System (NorthStar Medical Radioisotopes), a unique system for producing Technetium-99m (Tc-99m), the…
Abiraterone acetate (Zytiga, Janssen Pharmaceutical) in combination with prednisone has received FDA approval for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer (CSPC). Approval of the new indication is based on phase 3 data from the pivotal LATITUDE clinical…
The FDA has approved a label update for secukinumab (Cosentyx, Novartis) that includes data on treating moderate-to-severe scalp psoriasis, a difficult-to-treat form of the disease that affects approximately half of all psoriasis patients. The label update is based on the results of a dedicated phase…
The FDA has declined to approve Novartis’ generic formulation of fluticasone propionate/salmeterol (Advair, GlaxoSmithKline), according to a report from FiercePharma. Approval of the Novartis’ generic had been anticipated for the first half of 2018. Novartis said it has received a complete response…
More children than previously thought may suffer from the health effects that can result when women drink alcohol while pregnant, according to researchers at the University of California San Diego School of Medicine. Their study, published online in the Journal of the American Medical Association, found…
A scientific analysis found stronger evidence that compounds in kratom have opioid properties, according to FDA Commissioner Scott Gottlieb, MD, who added that the agency has now received 44 reports of deaths linked to the Asian plant. In November 2017, the FDA warned the public not to use kratom (Mitragyna…
Biogen Inc. says it will not develop natalizumab (Tysabri) for the treatment of acute ischemic stroke after the medication failed a phase 2b trial. Natalizumab, which made nearly $2 billion in 2017 sales, is part of Biogen’s franchise of multiple sclerosis (MS) drugs, a Reuters report noted. Biogen’s…
One hundred years ago, the deadliest influenza pandemic of all time made a ravaging march across the globe. The "Spanish" flu of 1918-19 infected an estimated one-third of the world's population and killed between 50 million and 100 million people, modern epidemiologists estimate. That raises the inevitable…
Positive results have been reported from a crucial immunotherapy trial that used a combination of two Bristol-Myers Squibb (BMS) drugs, nivolumab (Opdivo) and ipilimumab (Yervoy), to treat patients with a specific type of non–small-cell lung cancer patients. But previously undisclosed changes BMS…
Positive results have been announced from the phase 3 PROSPER trial in patients with nonmetastatic castration-resistant prostate cancer (CRPC). The results show that the use of enzalutamide (Xtandi, Astellas Pharma/Pfizer) plus androgen deprivation therapy (ADT) significantly reduced the risk of developing…
In a late-stage study, a combination of experimental drugs—encorafenib and binimetinib (Array BioPharma, Inc.)—kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as rival medicine vemurafenib (Zelboraf, Roche), according to…
Positive results have been announced from ACHIEVE I (UBR-MD-01), the first of two pivotal phase 3 clinical trials evaluating the efficacy, safety, and tolerability of Allergan’s orally administered ubrogepant 50 mg and ubrogepant 100 mg compared with placebo in a single migraine attack in adults.…

Pages